Jafron Biomedical Co.,Ltd. (SHE:300529)
China
· Delayed Price · Currency is CNY 21.97
-0.14 (-0.63%)
Apr 24, 2025, 2:45 PM CST
Jafron Biomedical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 724.21 | 820.2 | 436.49 | 889.56 | 1,197 | 875.24 | Upgrade
|
| Depreciation & Amortization | 124.97 | 124.97 | 94.79 | 73.99 | 54.06 | 36.73 | Upgrade
|
| Other Amortization | 19.18 | 19.18 | 18.19 | 8.63 | 4.68 | 2.17 | Upgrade
|
| Loss (Gain) From Sale of Assets | -3.64 | -3.64 | -6.72 | -0.86 | -0.98 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 6.24 | 6.24 | 27.07 | 7.86 | 1.15 | 0.48 | Upgrade
|
| Loss (Gain) From Sale of Investments | -43.11 | -43.11 | - | -10.51 | -28.72 | -15.19 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | - | -1.99 | 6.76 | 0.82 | Upgrade
|
| Other Operating Activities | -78.71 | 63.35 | 45 | 27.72 | 7.69 | -1.1 | Upgrade
|
| Change in Accounts Receivable | -8.22 | -8.22 | 277.22 | -7.9 | -110.41 | -83.41 | Upgrade
|
| Change in Inventory | 41.56 | 41.56 | -37.3 | -152.74 | -75.93 | -28.29 | Upgrade
|
| Change in Accounts Payable | 0.45 | 0.45 | 52.14 | 60.66 | 203.27 | 150.6 | Upgrade
|
| Change in Other Net Operating Assets | 35.49 | 35.49 | 10.87 | -8.59 | 8.27 | 22.35 | Upgrade
|
| Operating Cash Flow | 812.95 | 1,051 | 916.74 | 883.8 | 1,249 | 957.49 | Upgrade
|
| Operating Cash Flow Growth | -31.37% | 14.64% | 3.73% | -29.26% | 30.49% | 64.09% | Upgrade
|
| Capital Expenditures | -191.71 | -235.14 | -247.25 | -475.89 | -537.41 | -357.11 | Upgrade
|
| Sale of Property, Plant & Equipment | 6.73 | 5.34 | 12.6 | 6.91 | 0.99 | 0.81 | Upgrade
|
| Cash Acquisitions | - | - | - | -0.18 | - | - | Upgrade
|
| Investment in Securities | -1,643 | -908.45 | -15 | 163.26 | -133.8 | - | Upgrade
|
| Other Investing Activities | 8.87 | 10.78 | - | - | - | 15.19 | Upgrade
|
| Investing Cash Flow | -1,819 | -1,127 | -249.65 | -305.9 | -670.22 | -341.11 | Upgrade
|
| Short-Term Debt Issued | - | 1 | - | - | - | - | Upgrade
|
| Long-Term Debt Issued | - | 325.08 | 762.92 | 296.32 | 998.3 | - | Upgrade
|
| Total Debt Issued | 108.94 | 326.08 | 762.92 | 296.32 | 998.3 | - | Upgrade
|
| Long-Term Debt Repaid | - | -654.5 | -349.47 | -6.11 | -6.02 | - | Upgrade
|
| Net Debt Issued (Repaid) | -435.59 | -328.43 | 413.45 | 290.21 | 992.28 | - | Upgrade
|
| Issuance of Common Stock | 14.22 | 14.22 | 123.81 | 67.29 | 195.09 | 72.07 | Upgrade
|
| Repurchase of Common Stock | -371.28 | -371.28 | -382.58 | -5.19 | -500.13 | -8.29 | Upgrade
|
| Common Dividends Paid | -335.96 | -340.12 | -561.79 | -729.42 | -531.02 | -377.81 | Upgrade
|
| Other Financing Activities | 247.94 | 35.78 | -44.8 | 11.19 | 8.94 | 1 | Upgrade
|
| Financing Cash Flow | -880.67 | -989.82 | -451.91 | -365.93 | 165.18 | -313.03 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.62 | 0.43 | 0.01 | -0.04 | -0 | -0.04 | Upgrade
|
| Net Cash Flow | -1,886 | -1,066 | 215.19 | 211.93 | 744.37 | 303.32 | Upgrade
|
| Free Cash Flow | 621.24 | 815.85 | 669.49 | 407.91 | 712 | 600.37 | Upgrade
|
| Free Cash Flow Growth | -29.15% | 21.86% | 64.13% | -42.71% | 18.59% | 65.47% | Upgrade
|
| Free Cash Flow Margin | 25.04% | 30.47% | 34.83% | 16.37% | 26.61% | 30.78% | Upgrade
|
| Free Cash Flow Per Share | 0.80 | 1.04 | 0.84 | 0.51 | 0.89 | 0.74 | Upgrade
|
| Cash Income Tax Paid | 449.86 | 468.12 | 255.53 | 441.93 | 427.62 | 297.68 | Upgrade
|
| Levered Free Cash Flow | 351.56 | 510.67 | 535.7 | 18.61 | 228.28 | 252.21 | Upgrade
|
| Unlevered Free Cash Flow | 390.06 | 550.49 | 569.66 | 41.13 | 233.85 | 252.21 | Upgrade
|
| Change in Net Working Capital | 148.32 | 16.03 | -384.54 | 136.03 | 122.35 | 55.36 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.